GlobeNewsWire
20 Jul 2026, 21:50 UTC · 9h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
ADMA Biologics is accused of utilizing channel stuffing and an undisclosed related party distributor to artificially inflate reported revenue growth. — Allegations of accounting fraud and revenue manipulation typically lead to severe valuation resets and loss of investor trust.
-0.80A class action lawsuit has been filed against ADMA Biologics and its executive officers for alleged violations of the Securities Exchange Act of 1934. — Legal proceedings introduce significant litigation risk and potential financial liabilities for the company.
-0.50Cantor Fitzgerald downgraded ADMA Biologics from Overweight to Neutral following concerns over a short-seller report. — Analyst downgrades typically trigger immediate selling pressure and lower price targets.
-0.40Continue reading
6 related stories
Search tags
Culper Research claims ADMA Biologics had -3% real growth in 2025 compared to the 20% reported by the company. — A discrepancy of 23% in growth rates suggests a fundamental misrepresentation of the company's business health.
-0.40Which stocks this story touches
The company is facing a class action lawsuit alleging securities fraud, channel stuffing, and internal control failures, leading to significant stock price declines.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
7h ago
